Tachycardia
Return to Library
|
Free Tachycardia Articles |
|
|
|
|
Study results from University Hospital, Department of Cardiology update understanding of cardiomyopathy therapy
2009 JUL 20 - (NewsRx.com) -- Data detailed in 'A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine' have been presented. According to a study from France, "We present the case of a 67-year-old woman with cardiomyopathy induced by inappropriate sinus tachycardia (IST) and a particularly high average heart rate. The patient was resistant and/or intolerant to treatment with conventional rate-slowing medications." "We used ivabradine--a specific sinus node I(f) current inhibitor--and successfully lowered the heart rate (33 beats per minute mean heart rate decrease). Symptoms, systolic function, and heart rate variability parameters recovered dramatically. No side effect was noted," wrote P.F. Winum and colleagues, University Hospital, Department of Cardiology. The researchers concluded: "We suggest that ivabradine--evaluated in trials to treat stable angina--should be considered as a second-line treatment in patients with very symptomatic and refractory IST." Winum and colleagues published the results of their research in Pacing and Clinical Electrophysiology (A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing and Clinical Electrophysiology, 2009;32(7):942-4). For additional information, contact P.F. Winum, Centre Hospitalier Universitaire Caremeau, Dept. of Cardiology, Nimes Cedex 9, France. The publisher of the journal Pacing and Clinical Electrophysiology can be contacted at: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA. Keywords: France, Cardiomyopathy Therapy, Cardiology, Cardiomyopathies, Cardiomyopathy, Electrophysiology, Physiology, Sinus Tachycardia, Tachycardia, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
